Low-histamine diet supplemented with exogenous diamine oxidase enzyme is useful for treating migraine in patients with DAO Deficiency.
download pdf
Ann Nutr Metab 2018;73 (suppl 2); 1-93
A.Duelo; M.Berbel; H.Mantecon-Laviguerie; O.Comas-Basté; M.L.Latorre-Moratalla; M.T.Veciana-Noguès; M.C.Vidal-Carou.
Departament of Nutrition, Instituto Clónico del Déficit de DAO (ICDDAO), Sant Cugat del Vallés. Spain; Departament de Nutrició, Ciències de l’Alimentació i Gastonomia. Facultat de Farmàcia i Ciències de l’Alimentació.INSA-UB.XaRTA.Universitat de Barcelona.Santa Coloma de Gramanet. Spain
Spanish Nutrition Society SEÑ and the Catalan Association of Food Science (ACCA), Barcelona, Spain, june 27-29, 2018
Introduction:
Low-histamine diets and/or exogenous diamine oxidase (DAO) supplementation are currently used to treat symptoms of histamine intolerance (IH), a disorder in histamine homeostasis that increases its plasma levels, mainly dou to DAO deficiency. Headache is the most recognized symptoms.
Objectives:
To assess the effectiveness of a low-histamine diet plus a DAO enzyme supplement on the remision of migraine in subjects with DAO deficiency.
Methods:
An intervention study was carried out in 212 individuals with a migraine diagnosis by a neurologist according to the International Classification of Headache Disorders and wih DAO deficiency (DAO <80 HDU/ml). Subjects followed a 3-month low-histamine diet based on the exclusion of foods considered rich in histamine or other biogenic amines and usually related to the onset of HI symptoms, such as fermented products (cheese, dry-fermented sausage, wine, beer), semi-preserved and canned fish, shellfish, certain fruits and vegetables (spinach, tomato, egg-plant, avocado, citrus, bananas, strawberries, pineapple, nuts) and chocolate. A DAO supplement was administrered before break-fast, lunch and dinner. Outcomes assessed were duration and number of attacks and perception of pain intensity with a score-scale fom 0 (absence) to 10.
Results:
Most subjects showed and improvement in migraines after the 3-month treatment: 34.9% reported complete remission and another 35.8% had a reduced number of migraines episodes per month of less duration and pain intensity. The treatment was less successful in 29.3% of patients. On average, when comparing baseline and final values after treatment, all outcomes were significantly reduced: 8 to 2 attacks per month, 24 to 3 hours of pain and 8 to 4 in pain intensity scoring.
Conclusions:
A low-histamine diet supplemented with the DAO enzyme for three months was useful in reducing the number of attacks, duration and intensity of pain in migraineous patients with DAO deficiency.
DOI: 10.11.59/000490752